ClinicalTrials.Veeva

Menu
S

Strathfield Retina Clinic | Strathfield, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Faricimab
APL-2
KHK4951
Triamcinolone Acetonide
Aflibercept
Ranibizumab
Pegcetacoplan
Dexamethasone
JNJ-81201887
IBE-814

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 19 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in pa...

Enrolling
Choroidal Neovascularization Secondary to Pathologic Myopia
Procedure: Sham Procedure
Drug: Faricimab

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Enrolling
Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.

Enrolling
Diabetic Macular Edema
Drug: Faricimab

Trial sponsors

Roche logo
A
C
Kyowa Kirin logo
Bayer logo
Ionis Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
McMaster University logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems